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Abstract: Viral hepatitis represents an important health problem in the South Mediterranean 
countries,  Egypt,  Libya,  Tunisia,  Algeria  and  Morocco.  Emerging  natural  history  and 
epidemiological information reveal differences in the overall epidemiology, risk factors and 
modes of transmission of viral hepatitis A, B, C, D, E infections in the South Mediterranean 
region.  The  differences in  the  in  incidence  and  prevalence  of viral  hepatit
African  countries  is  attributed  to  variations  in  health  care  and sanitation  standards,  risk 
factors  and immunization  strategies.  The  active continuous  population  movement through 
travel, tourism and migration from and to the South Mediterra
the  spread  of  infections  due  to  hepatitis  viruses  across  borders  leading  to  outbreaks  and 
emergence  of  new  patterns  of  infection  or  introduction  of  uncommon  genotypes  in  other 
countries, particularly in Europe. 
Introduction:  In  There  are  some  similarities  but 
also  there  substantial  di€erences  between  South 
Mediterranean countries.  The epidemiology of viral 
hepatitis  in  south  Mediterranean  countries  is 
dynamic  and  affected  by  many  factors  including 
hygiene,  socioeconomic  status  and  vaccination 
coverage. For example, hepatitis B (HBV) 
hepatitis C (HCV) viruses 
3 have a high tendency to 
persist  and  establish  chronic  hepatitis  with  long
term  sequels.  HBV- and  HCV-related  chronic 
hepatitis is considered the main cause of cirrh
hepatocellular  carcinoma  (HCC)  and  liver 
transplantation in the region
2,3. While HCV related 
liver disease represents a huge health and economic 
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Viral hepatitis represents an important health problem in the South Mediterranean 
countries,  Egypt,  Libya,  Tunisia,  Algeria  and  Morocco.  Emerging  natural  history  and 
miological information reveal differences in the overall epidemiology, risk factors and 
modes of transmission of viral hepatitis A, B, C, D, E infections in the South Mediterranean 
region.  The  differences  in  the in  incidence  and  prevalence  of viral  hepatitis  across  North 
African  countries  is  attributed to  variations  in  health  care  and sanitation  standards,  risk 
factors  and immunization  strategies.  The  active continuous population  movement through 
travel, tourism and migration from and to the South Mediterranean countries contribute to 
the  spread  of  infections  due  to  hepatitis  viruses  across  borders  leading  to  outbreaks  and 
emergence  of  new  patterns  of  infection  or  introduction  of  uncommon  genotypes  in  other 
countries, particularly in Europe. 
There  are  some  similarities  but 
€erences  between  South 
Mediterranean countries.  The epidemiology of viral 
hepatitis  in  south  Mediterranean  countries  is 
dynamic  and  affected  by  many  factors  including 
nd  vaccination 
coverage. For example, hepatitis B (HBV) 
1,2 and 
have a high tendency to 
persist  and  establish  chronic  hepatitis  with  long-
related  chronic 
hepatitis is considered the main cause of cirrhosis, 
hepatocellular  carcinoma  (HCC)  and  liver 
. While HCV related 
liver disease represents a huge health and economic 
problem in Egypt, HCV is not considered a public 
health problem in Morocco. In this review, we will 
explore  the  epidemiology,  patterns  and  trends  of 
viral hepatitis in the South Mediterranean countries 
namely,  Egypt,  Libya,  Tunisia,  Algeria  and 
Morocco.
Hepatitis A Virus (HAV) Infection
HAV still represents a public health problem in 
the South Mediterranean region which is considered 
an  area  with  high  HAV  prevalence.
frequent  travel  acquired  infection  that  has  caused 
several   outbreaks  among  European  tourists.
HAV  infection  is  largely  acquired  through  fecal
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HAV still represents a public health problem in 
region which is considered 
an  area  with  high  HAV  prevalence.
4 HAV  is  a 
frequent  travel  acquired  infection  that  has  caused 
several   outbreaks among  European tourists.
5,6,7,8,9
HAV  infection  is  largely  acquired  through  fecal-Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
oral  transmission.
5 Consumption  of  contaminated 
food  or  raw  sea  food  or  drinking  contaminated 
water represents the main routes of transmission in 
the South Mediterranean region. HAV is a resilient 
virus  that  survives  for  prolonged  periods  in  food 
and drink.
7,8 HAV infection in South Mediterranean 
countries has been characterized with a lifetime risk 
of infection greater than 90%. Most infections occur 
in  early  childhood  and  those  infected  may  not 
experience any noticeable symptoms. Epidemics are 
uncommon  because  older  children  and  adults  are 
generally immune. Disease rates in these areas are 
low and outbreaks are rare. Recently, a shift from 
high  to  intermediate  HAV  endemicity  patterns  is 
observed  in  countries  with  transitional  economies 
such  as  Egypt,  Tunisia  and  Morocco.  In  these 
countries,  the  improvement  of  economic  and 
sanitary conditions has been associated with decline  
in early  childhood HAV infections that started to 
occur  in  older  age  groups.  Immunization  against 
HAV is not incorporated in the routine childhood 
immunization programs in any of the countries of 
the region. 
HAV  in  Egypt:  HAV  is  endemic  in  Egypt  and 
represents  a  major  cause  of  acute  viral  hepatitis 
being  responsible  for  more  than  half  of  acute  s 
hepatitis cases. HAV genotype IB is the prevalent 
genotype in Egypt. Person-to-person transmission, 
consumption  of  food  contaminated  in  fields  or 
through infected food handlers is very common as 
well  as  consumption  of  contaminated  mollusks 
(clams, oysters) and unsafe drinking water represent 
the major routes of HAV transmission in Egypt. In 
children, day care centers contribute to HAV spread 
among  young  children,  siblings  and  parents  of 
daycare center attendees.
10,11,12
Generally, HAV is acquired early in life with 
most infections occurring between 5-15 years with 
no  sexual predilection.  However,  it  is  unknown 
what proportions of infected persons are aware of 
their  infection  given  acute  HAV  tends  to  be 
asymptomatic particularly  in children <5  years of 
age.
10,13 Thus, many individuals are neither tested 
nor reported. Individuals living in rural areas are at 
higher risk of hepatitis A infection compared to the 
urban  population  due  to  overcrowding,  poor 
sanitation,  certain  social  practices,  and  lack  of  a 
reliable clean water resource.
12 A study showed that 
in Egypt, HAV could be detected in 72%, 50% and 
43%  of  raw  sewage,  Nile  and  treated  effluent 
sewage samples respectively.
14. posing  a potential 
health risk for people.
Within the Egyptian socioeconomic framework 
and social class structure, differing frequencies of 
hepatitis A virus infection with different age peaks 
are  observed.  In  rural  or  semi-urban  regions  and 
lower  socioeconomic  classes,  most  of  the 
population is exposed to HAV at a very young age, 
acquires the infection with minimal or no symptoms 
and develops immunity.
12,13 Cross-sectional studies 
conducted  in  rural  areas  revealed  very 
high‐prevalence of anti-HAV IgG reaching 100% of 
adults.
13 Consumption  of  common  village  water, 
use  of  indoor  dry  pits,  and  contamination  of 
drinking water with sewage represent the major risk 
factors for HAV acquisition in rural Egypt.
16,17 In 
the  past  2  decades,  there  has  been  significant 
emphasis  on  improving  sanitation  measures  and 
hygiene  in  Egypt  coupled  with  extension  of  
municipal  potable  water,  sewage,  and  solid‐waste 
management  systems  projects.  Therefore,  in  large 
Egyptian  cities  and  among  high  social  classes, 
children  are  infrequently  exposed  to  hepatitis  A 
virus at a young age with subsequent decline in herd 
immunity and a change to the epidemiology of the 
illness  with  steady  increases  in  the  mean  age  of 
occurrence of illness attributed to acute hepatitis A 
virus infection.  Thus, in urban Egypt despite the 
overall decrease in the incidence of HAV infection, 
more HAV infections are encountered at older age 
groups.  
HAV  infection  in  children  and  adolescents  is 
mostly  asymptomatic  or  might  present  as  flu-like 
illness  or  anicteric  hepatitis.  Symptomatic  cases 
with jaundice that terminates in complete resolution 
are less common in young age groups. However, in 
spite  of  this  jaundice,  the  patient  feels  well.  A 
proportion of patients who acquire infection at older 
may  develop  symptomatic  HAV  infection  with 
prolonged clinical course and jaundice or may have 
recurrence  within  a  short  period  of 
improvement.
5,11,12 Fulminant hepatitis due to HAV 
is  very  rare  in  Egypt  although  recently  few 
fulminant  HAV  cases  that  required  liver 
transplantation have been reported in adult patients 
who acquired the infection at older age. 
Currently,  immunization  for  HAV  is  not 
included  within  the  compulsory  children 
immunizations  programs  in  Egypt    due  to  the 
limited clinical seriousness of the infection among 
the general Egyptian population.
11 Immunization is 
reserved to special groups, namely household/close 
contacts  of  patients  with  HAV,  patients  with 
chronic liver disease or HCV infection. Newborns 
and    children  may  be  immunized  depending  on 
epidemiology. 
Recently several outbreaks of HAV have been 
reported  among  European  travelers  and  European Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
tourists returning from Egypt. A survey conducted 
in 13 European countries traced the source of the 
outbreaks to food or drinks in hotels or Nile cruises. 
The reported hepatitis A attack rates varied between 
tourists  from  different  European  countries.  Thus, 
the health authorities in EU countries recommended 
active  vaccination  with  hepatitis  A  vaccine  for 
people travelling to Egypt. Adoption of the public 
health policies and immunization prior to travel are 
likely  to  reduce  the  potential  of  acquiring  HAV 
infection by non-immune travelers.
6,7,8,9,18
HAV  in  Libya:  Similar to  Egypt,  most  HAV 
infections are  acquired during  childhood. Surveys 
showed  that HAV antibodies could be detected in 
60-70% of three-year old children.  By the age of 
7years  almost  100%  of  children  are  HAV 
immune.
19
HAV in Tunisia: In Tunisia, there is no national 
program  for  virological  surveillance  of  hepatitis 
cases  or  assessment  of  epidemiology  the of  these 
infections.  However,  some  studies  showed  that 
HAV  prevalence  rates  range  between  84.0  and 
92%.
20,21,22 Primary infection with HAV in Tunisia 
is progressively shifting to older ages, probably due 
to the improvement of sanitary conditions. A survey 
conducted to assess the prevalence of HAV among 
Tunisian  children  and  adolescents  revealed  an 
overall seroprevalence among this population was 
60% (44%, in children < 10 years old, 58% in those 
10-15 years of age, and 83% in those > 15 years of 
age). Prevalence rates varied according to areas of 
residence. More than 90% of those living in rural 
areas had antibodies to HAV compared to 30-50% 
among those  living in the urban areas. The lowest 
anti-HAV  prevalence  rates  are  found  in  coastal 
regions probably due to the higher socioeconomic 
level of the population living in such regions. 
20 To 
date, mass vaccination programs for HAV are not 
indicated in Tunisia. 
Several  outbreaks  of  HAV  infection  were 
erupted among European tourists following visits to 
Tunisia. By  age-group, the  highest  incidence was 
found  in  unprotected  children  travelers  0  to  14 
years. Thus, travelers, and especially children, are 
strongly  encouraged  to  receive  HAV  vaccination 
before travelling to South Mediterranean countries 
including Tunisia.
23,24,25
HAV in Algeria: Hepatitis A is common in Algeria 
where  96%  of  individuals  have  anti-HAV 
antibodies. Patients come into contact with the virus Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
before the  age  of  10. No symptoms  are found  in 
95%  of  cases  while  icteric  cases  are  mostly 
encountered  among  infants  and  young 
children.
26,27,28
HAV  in  Morocco:  Morocco  is  an  intermediate 
endemic area for HAV infection.  The prevalence of 
anti-HAV  antibodies  among  Moroccan  children 
varies  with  age.  Anti-HAV  antibodies  could  be 
detected in 45% and 70%  in children less than 6 
years and  children between 7-14 years respectively. 
Socioeconomic  factors,  city  dwelling  and  parents 
education  correlated  with  the  prevalence  of  anti-
HAV-IgG.  Thus, Morocco is entering a transitional 
phase with less children exposed to HAV at early 
childhood. Introduction of hepatitis A vaccination 
in early childhood might reduce the prevalence of 
this infection and prevent outbreaks 
.29
Hepatitis B Virus (HBV) Infection 
Hepatitis B virus (HBV) is an ubiquitous virus 
with a global distribution. Of the approximately 2 
billion people who have been infected worldwide, 
more  than  350  million  are  chronic  carriers  of 
HBV.
30 Approximately 15-40% of infected patients 
will  develop  cirrhosis,  liver  failure,  or 
hepatocellular  carcinoma  (HCC).
31 HBV  infection 
accounts for 500.000 to 1.2 million deaths each year 
and is the 10
th leading cause of death worldwide.
30
South  Mediterranean  countries  have  been 
previously  been  classified  as  a  high  endemicity 
countries.  for  HBV.
30,31 Horizontal  transmission 
used  to  occurs  among  children  and  adults.  This 
results in chronic carriage, but less often than when 
infection occurs vertically or perinatally, leading to 
a  gradual  dwindling  of  the  reservoir  of  chronic 
carriers  with  fewer  long-term  complications  and 
deaths.  There  is  a  correlation  between  the 
endemicity  level  of  HBV  infection  and  the 
frequency  of  HBV  related  chronic  hepatitis  and 
cirrhosis.  In  fact,  where  the  endemicity  level  is 
intermediate or high, HBV infection is common in 
newborn babies and children and in these groups, 
progression towards chronicity is frequent. 
31,33 On 
the  other  hand,  late  onset  of  infection  such  as  a 
result  of  sexual  activity  would  result  in    chronic 
carrier rates of  3±5% become, but 30% may show 
signs and symptoms of acute infection.
Recent  surveys  suggest  a  shift  in  the  HBV 
endemicity  patterns  in  most    Southern 
Mediterranean  countries  from  high  endemicity  
towards  intermediate  or  low  endemicity 
patterns
33with  some  limited  hyperendemic 
pockets.
30 Since  the  early  nineties  of  the  last 
century,  Tunisia,  Morocco,  Libya  and  Egypt 
adopted  highly  effective  infants’  vaccination 
programs  which were sometimes extended to the 
several  paediatric and adult  groups, producing a 
dramatic decrease in the incidence of HBV in birth 
cohorts  born  after  implementation  of  the 
vaccination programs.  . Furthermore, the increases 
in the public awareness and modes of transmission 
of  HBV  in  addition  to  the  improvements  in 
healthcare  infrastructure  and  the  socioeconomic 
conditions contributed to reduce the infection rate in 
the region. 
HBV  is  divided  into  eight  genotypes  (A-H) 
according to overall nucleotide sequence variation 
of  the  genome.  The  genotypes  have  a  distinct 
geographical distribution and are used in tracing the 
evolution and transmission of the virus. Genotype D 
in  is  prevalent  in  North  African  countries. 
Differences  between genotypes  affect  the  disease 
severity,  course  and  likelihood  of  complications, 
and  response  to  treatment  and  possibly 
vaccination.
34,35
HBV in  Egypt:  The  incidence  and  prevalence  of 
HBV showed recent decline following the effective 
HBV  immunization  program.  In  1985,  a  study
36 
conducted  on  1,866  apparently  healthy  Egyptians 
from  Upper  and  Lower  Egypt  showed  that  the 
overall prevalence rate of HBsAg was 10.1%. with 
higher rates in Upper Egypt (11.7% ) compared to 
the Nile Delta (8.0%). HBsAg was more frequent in 
young  males  than  females  and  the  prevalence 
gradually  increased  with  age.  A  recent  study
37
conducted  20  years  later  screened  55,922 
potentially healthy asymptomatic blood donors  for 
HBsAg.   The  cumulative  seroprevalence  of  HBV 
infection  was  1.3%  with  decline  in  the  annual 
seroprevalence  throughout  the  study  period  from 
2.3% to 0.9%.  Another study 
13that compared the 
frequencies of hepatitis viruses as etiological agents 
for  acute  viral  hepatitis  over  the  past  2  decades 
found that the frequency of acute hepatitis B virus 
infection decreased from 43.4% in 1983 to 28.5% in 
2002 (P<.01).  
The significant decline in HBV rates indicates 
the effectiveness of the universal hepatitis B virus 
immunization of infants that was initiated in 1991. 
Cross-sectional  studies  conducted  over  a  decade 
among schoolchildren in an endemic area in Egypt 
for screening of HBV virus markers also showed a 
significant  decrease  of  HBV  prevalence  among 
school children confirming the effectiveness of the 
immunization  campaigns.
38 To  evaluate  the 
protective  efficacy  of  hepatitis  B  vaccine,  720 
children  aged  10  years  who  were  vaccinated  in 
infancy  were  tested  for  hepatitis  B  serologic Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
markers.  Among  the  vaccinated  children,  37.9% 
had  protective  anti-HBs,  0.6%  had  HBsAg  while 
HBV infection occurred in 6.8% of the vaccinated 
children and it induced a boosting effect on anti-
HBs  level.  only  of  the  vaccinated  children.
39
Despite the decline in the incidence and prevalence 
of HBV in Egypt,  higher HBV prevalence rates are 
encountered  in  special  patient  groups  such  as 
patients undergoing  hemodialysis 
40, patients with 
hematological  malignancies 
41,  hemophiliacs  and 
injecting drug users (IDUs).
42
Adults  particularly  from  Upper  Egypt  had 
higher prevalence of HBV. In Egypt, various risk 
factors for  HBV  transmission  were  identified 
including shaving at barbers shops, injecting drug 
use,  recent  (<1 year)  marriage,  home  deliveries, 
occupational or nosocomial exposure in health care 
facilities.
13,43
In Egypt, HBV genotype D is the predominant 
HBV  genotype  (37.1%)  followed  by  genotype  B 
that constituted 25.7%. and mixed D & B infections 
in  15.7%  of  patients.  HBV  genotypes  A  and  C 
infections were the less observed constituting 10% 
and  8.6%  respectively  of  the  total  infections.  In 
children  with  pediatric  malignancies,  a  relatively 
high  prevalence  of  mixed  A/D  genotype 
infections.
41
The association of HBV and liver cancer is well 
documented.  The  burden  of  hepatocellular 
carcinoma  (HCC)  has  increased  in  Egypt  with  a 
doubling in the incidence rate in the past 10 years. 
The  prevalence  rates  for  HBV  and  HCV  were 
25.9% and 78.5% among HCC cases. Among HCC 
cases,  HBV  significantly  decreased  over  time 
(p=0.001) while HCV did not, suggesting a shift in 
the  relative  influences  of  these  viruses  in  HCC 
etiology in Egypt.
44
HBV in Libya: Libya is considered a country with 
intermediate  endemicity  for  HBV.  The 
seroprevalence  of  HBsAg  among  general 
population in Libya ranges between 5.8% and 1.3% 
depending  on  the  method  of  diagnosis  and  the 
geographic  region. 
45,46 However,  recent  surveys 
reported  an  over  all  prevalence  of    2.2%    with 
120.000-150.000 chronic HBsAg carriers in Libya 
associated with viral transmission. 
47 HBV infection 
is related to male gender, use of skin scarifications, 
high-risk  behaviors,    unsafe  injections,  history  of 
blood transfusion, family history of hepatitis B or 
contact  with  hepatitis  B  patients.  Vertical 
transmission  is  responsible  for  some  cases  of 
neonatal  HBV  infections.  In  Libya,  universal 
newborns hepatitis B vaccine was introduced since 
1993.  The  vaccine  was  also  recommended  to  be 
used  to  household  contacts  of  HBV-infected 
individuals and healthcare workers. 
47
HBV  genotype  D  is  the  prevalent  HBV 
genotype  as  in  other  countries  in  North  Africa. 
HBV  infection  is  responsible  for  the  majority of 
chronic liver disease cases in the country. A high 
prevalence  rate  of  HBeAg-negative/anti-Hbe-
positive  chronic  hepatitis  B  has  been  reported, 
which accounted for 80% of chronic HBV patients. 
HBV is a leading cause of hepatocellular carcinoma 
in Libya.
46,47
HBV in Tunisia: Tunisia is considered a country 
with  intermediate  endemicity  of  HBV  infection.  
Many infections are clustered among children and 
teenagers.  Geographically,  HBsAg  seropositivity 
varied throughout the country, ranging from 3% to 
13%  with higher  prevalence  in  the  south  and 
central-west  regions.  Studies  conducted  in  the 
eighties  and  nineties  showed  high    overall 
seroprevalence of HBV in Tunisia reaching 37.5%. 
48 .However,  a  more  recent  survey  estimated  the 
overall  hepatitis  B  carrier  rates in  the  general 
Tunisian    population  at  3%  to7%  suggesting  a 
decline in HBV in Tunisia. This could be attributed 
to  the  hepatitis  B  vaccination    which  was 
incorporated in the national schedule of new-born 
vaccination in 1995. 
52 
The  magnitude  of  vertical  and  perinatal 
transmission  of  HBV  is  not  clear  but  has  been 
addressed in a study conducted on a cohort of 2303 
Tunisian  pregnant  women  of  whom  4%  were 
HBsAg  positive  and  1.4%  were  vaccinated 
previously against hepatitis B. Analysis of the risk 
factors  revealed  association  between  the  HBsAg 
status and presence of intrafamilial hepatitis cases 
(p<0.05). The maternal DNA levels ranged from 34 
to  10
8copies/ml  to  10 
4 copies/ml.  Vertical  and 
perinatal transmission of HBV in the first 3 months 
of life occurred in 0.4% of 177 mother and child 
pairs.  HBV  seroprevalence  was  10.7%  in  infants 
under 5 years old and increased with age rapidly till 
25 years of age and then more slowly in adulthood, 
reaching 54% for people aged over 40 years. 
51
HBV  genotypes,  (D,  A,  and  E)    have  been 
detected in Tunisia with prevalence rates 80%, 8%, 
and 9%, respectively indicating that genotype D is 
the  most  prevalent  HBV  genotype.
50    A  novel 
subgenotype,  D7,  was  the  most  common 
subgenotype  found  in  asymptomatic  Tunisian 
HBsAg  carriers. 
53  .A  high  frequency  of  HBV 
precore mutants has been reported from Tunisia.
49 
Precore mutants have beeb more frequently found 
in chronically and in acutely infected individuals, in 
patients with severe and asymptomatic infections, in Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
HBeAg  positive  as  well  as  HBeAg  negative 
individuals.
50
HBV in Algeria: Algeria is considered a country 
with intermediate endemicity for  HBV.  A survey 
was conducted to  assess  the  serologic  markers  of 
hepatitis B (HBsAg , anti-HBc in 1,112 apparently 
healthy blood donors and 715 pregnant women in 
different regions in Algeria. HBs Ag was detected 
in 3.6 % of blood donors and 1.6 % of pregnant 
women while anti-HBc antibodies in 13 % of blood 
donors and 11.1 % of pregnant women.
54 Another 
Algerian  study  evaluated  the  characteristics  of 
hepatitis B viral strains in chronic carrier patients 
from  North-East  Algeria.  The  median  age  of 
patients was 35 years and 80% of them had normal 
transaminase  level.  Liver  histology  revealed 
different necroinflammatory changes in 63% of the 
patients and established cirrhosis in 21%. "Precore" 
mutant  serological  profile  without  HBe  Ag  was 
detected  in  87%  of  patients.  Genotype  D  was 
predominant (93%) followed by genotype A (5%) 
and  E  for  one  patient.  Algerian  strains  clustered 
independently  from  other  genotype  D  reference 
sequences, suggesting a possible new D subtype.
55
HBV in Morocco: Morocco is among the countries 
with  intermediate/low  endemicity  of  HBV 
infection. To date, there is no concrete figures for 
overall  prevalence  rates  of  HBV  in  Morocco. 
However, some studies showed that 2% of chronic 
haemodialysis  patients  treated  in  a  haemodialysis 
unit  in  Casablanca  show  evidence  of  HBV 
infection. 
58 Genotype D is the most prevalent HBV 
genotype  (97.5%)  followed  by  genotype  A,  a 
pattern which is consistent with the predominance 
of  genotype  D  in  the  Mediterranean  basin. 
56
Phylogenetic analysis based on pre-S/S sequences 
revealed that genotype D in Morocco differed from 
others D strains subgenotypes (D1, D2, D3 and D4). 
Pre-core mutant are highly prevalent in Morocco as 
a  study  showed  that  HBeAg-negative/anti-HBe-
positive  and  HBV  DNA  positive  was detected  in 
86% of 91 patients with chronic hepatitis B. 
57 
Hepatitis C Virus (HCV) Infection
Hepatitis  C  virus  (HCV)  is  a  major  public 
health problem and the primary causative agent of 
chronic  liver  disease  in  Southern  Mediterranean 
countries.  Compared  to  other  hepatitis  viruses, 
HCV  shows  vast  variations  across  south 
Mediterranean  countries.  Geographically,  HCV 
prevalence rates decrease along the Mediterranean 
coast from the East towards the West. Egypt has the 
highest  HCV  prevalence  worldwide  with  13%  of 
Egyptians are infected while the prevalence of HCV 
in Morocco and Algeria is 1-2%.  The incidence of 
HCV in the individual countries is hard to estimate 
accurately given that many patients with acute HCV 
infection  are  asymptomatic.  The  risk  factors  and 
modes  of  transmission  differ  among  the  5  south 
Mediterranean  countries.  HCV  genotypes 
distribution also differ from  prevalence of HCV G4 
in Egypt and the predominance of genotype 1a or 
1b in western areas such as Tunisia and Morocco       
HCV in Egypt: Egypt  has the highest prevalence of 
HCV in the world (13%). 
59,60 The current sequence 
diversity  and  phylogenetic  tree  structure  of  HCV 
G4a in Egypt is compatible with the introduction of 
HCV  into  that  population  through  parenteral 
treatment  for  schistosomiasis with  non  disposable 
and  poorly  sterilized  needles  in  the  1950s  and 
1960s. 
62,63 Although  subtype  4a  is  the  dominant 
Egyptian HCV strain, recent studies revealed that 
other subtypes are also present, indicating that HCV 
G4  in  Egypt  is  extremely  variable.
64,65,66  HCV 
accounts for 31% of acute viral hepatitis cases in 
Egypt. 
676 In  Egypt,  high  rates  of  infection  are 
observed  in  all  age  groups  including  young 
individuals,  indicating  an  ongoing  high  risk  for 
acquiring HCV infection. More than 60% of acute 
HCV infections are in persons below the age of 25 
yr. 
,68,69 High  incidence  rates  (14.1  per  1,000 
person-years)  have  been  detected  in  Egyptian 
children  younger  than  10  yr  of  age  living  in 
households with an anti-HCV-positive.
68 This high 
incidence  in  young  persons  could  lead  to  future 
increases in chronic disease in these individuals and 
persistence of the high magnitude of the burden of 
HCV-related  chronic  disease  in  Egypt.  The 
prevalence  of  HCV  in  both  genders  is  not  well 
documented although some studies showed higher 
HCV incidence among men and high spontaneous 
resolution n rates in women.
69
In  Egypt,  relatively  higher  rates  of  sexual 
transmission  in  Egypt  have  been  reported  and 
reflect  the  higher  background  prevalence  in  this 
country.  In  rural  Egypt,  sexual  transmission 
between monogamous spouses ranged between 3% 
and  34%  (95%  CI  0–49).
70,71 Acute  HCV  is 
associated with a high temporal risk of transmission 
of  HCV  to  sexual  partners.  Sexual  transmission, 
confirmed by phylogenetic analysis, was detected in 
15%  of  sexual  partners  of  individuals  with  acute 
HCV. 
71  Although some cases of acute HCV have 
been related to sexual transmission, the degree to 
which  sexual  transmission  of  HCV  occurs  is 
controversial  because  sexual  transmission  is 
difficult to confirm given that partners might have 
other  risk  factors  for  HCV  transmission  such  as Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
IDU.  Phylogenetic  analysis  to  identify  genetic 
relatedness  of  HCV  viral  isolates  in  partners  is 
required to confirm sexual transmission. All studies 
on the sexual transmission of hepatitis C are limited 
by the potential of the confounding variable of IDU 
or  shared  items  such  as  razors  and  other  items 
among sexual partners. 
72
HCV  infection  has  been  associated  in  Egypt 
with  health-care-related  procedures  performed  by 
traditional  healers  and  folk  medicine  providers, 
acupuncture,  tattooing,  body  piercing,  and 
commercial  barbering.  Informal  health-care 
providers  and  traditional  healers  perform  services 
that may be associated with HCV transmission such 
as  injections,  dentistry,  wound  treatment, 
circumcision,  excision,  and  scarification. 
73,74 In 
rural Egypt, about 50% of deliveries are attended by 
traditional  birth  assistants.
74 Lack  of  appropriate 
cleaning  and  disinfection  of  equipment  used  in 
these  procedures  contribute  to  HCV  transmission 
and the emergence of new HCV cases.
71
Infection  with  HCV  is  an  important 
occupational  hazard  for  Egyptian  health-care 
workers.  The  risk  of  occupational  HCV 
transmission increases with deep injuries and after 
procedures  involving  hollow-bore  needles.  In 
Egypt, occupational transmission among health-care 
workers through  needlesticks  and  sharps  injuries 
contributes  to  new  HCV  cases  given  that 
needlestick-prevention devices are not yet adopted 
most hospitals and health-care units in addition to 
inadequate  compliance  with  universal,  standard 
precautions in some health facilities. 
75,77,78
The role of intrafamilial HCV transmission is 
still  controversial.  However,  several  studies 
reported  HCV  spread  in  families  with  HCV-
infected index cases.  In rural Egypt, intrafamilial 
HCV transmission is considered an important route 
of  transmission  where  living  in  a  house  with  an 
infected family member is  a risk  factor for  HCV 
transmission.  Analysis  of  data  collected  during 
surveys of  Egyptian  rural  communities  show  that 
children whose parents had antibodies to HCV were 
at  higher risk  for  contracting  anti-HCV  than 
children whose parents did not.
75 
HCV  in  Libya:  In  1994,  a  study  that  tested  266 
healthy  Libyan  subjects  for  anti-HCV  antibodies 
found that 21 (7.9%) subjects had evidence of HCV 
infection  suggesting  a  high  frequency  of
'community-acquired'  HCV  in  the  normal  Libyan 
population. 
79    However,    the  national  sero-
epidemiological  survey  in  2006  showed  that  the Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
prevalence  of  HCV  antibodies  in  the  general 
population  in  Libya  was  1.2%. 
80      In  a  Tripoli, 
screening of    sera collected over a  2 year  period 
showed  that  the  prevalence  HCV  of  1.6%,  1.2%, 
2%  among  the  general  population,  blood  donors, 
hospital  health  care  workers  respectively.  HCV 
prevalence was 20.5% among renal dialysis patients 
and 10.8% in the multiple blood transfusion group. 
81 History  of  hospitalization  and/or  surgical 
procedures risk (33%) , history of blood transfusion. 
(22.7%),  past  history  of  intravenous  drug  abuse 
(IVDA) ( 15% ) and history of dental procedures. 
(15.9%) 
81  or  medical  waste  handling  82  were 
important risk factors for HCV infection. It is not 
clear  whether  the  discrepancy  in  prevalence  rates 
between the 1994 report and the 2006 survey report 
is  due  to  actual  reduction  or  changes  in  the 
sensitivity  and  specificity  of  the  diagnostic  tests 
used. 
The largest documented outbreak of nosocomial 
HIV  transmission  to  approximately  400  Libyan 
children in 1998 was coupled by HCV and/or HBV 
transmission. 
83Among the  HIV infected  children, 
47%  and  33%  had  HCV  and  HBV  coinfection 
respectively. Vertical transmission was ruled out by 
analysis of parents' serology. Prospective follow up 
of  160 HIV/HCV coinfected showed that half of 
the  children  progressed  to  moderate  or  severe 
immunosuppression  and/or  moderate  or  severe 
clinical  symptoms  three  years  after  infection.  In 
those who  progressed during follow-up, 85% had 
done  so  within  three  years  of  infection.  Children 
progressing  to  moderate  or  severe 
immunosuppression and/or clinical symptoms were 
significantly more likely to be receiving ART. 
83
The major HCV genotypes circulating in Libya 
include  genotype  1  (G1)  in  30.9%  of  cases  
followed by G4 (29.2%). Genotype 2 in 19.3% and 
G3 in 13.6%.  The frequency of HCV genotype 4 in 
the  Libya  might  suggest  introduction  from 
neighboring  countries  mostly  from  Egypt  and 
Central  African  countries,  where  genotype  4  is 
predominant.  Few  of  the  Libyan  isolates  were 
closely  related  to  the  European  ones  where  the 
majority of patients are infected with genotype 1, 2 
or 3.
83
HCV  in Tunisia: The seroprevalence of HCV 
in the Tunisian general population is low (0.4%). 
48
However, another study showed high prevalence of 
HCV  infection  among  Tunisian  dialysis  patients 
with rates of 51% suggesting that the spread may be 
nosocomial rather than transfusion-related. 
85 HCV  
isolates  from  93  Tunisians,  including  16 
haemophiliacs,  were  genotyped  In  non-
haemophiliacs, subtype 1b was largely predominant 
(79%), types 1a, 2a, 2b, 3a and 4a occurred much 
less  frequently  at  5,  7,  3,  3  and  1%  of  cases, 
respectively.  In the  group  of  haemophiliacs,  aco-
dominance between subtypes 1a and 1b was noticed 
(38%). 
85
HCV in Algeria: The prevalence of HCV in Algeria 
is not high. In a 1995 survey of  1,112 apparently 
healthy blood donors and 715 pregnant women in  
Algeria 
54,  anti-HCV  antibodies  were  detected  in 
0.18  %  of  blood  donors and  0.19  %  of  pregnant 
women. Recently, the Algerian Ministry of health 
estimates the prevalence of HCV in Algeria to be 
around 2.5%.
86 
Occupational  exposure  and  health  related 
transmission seem important risk factors for HCV 
transmission in Algeria. A survey on the frequency 
of  occupational  exposure  to  HCV  among  health 
care personnel in an Algeria hospital revealed 108 
exposures  in  2  years.  Needle  stick  injuries 
represented 81% of cases. Source patient serology 
was unknown in most of the cases, negative in 9% 
of  cases  and  positive  in  10%  of  cases.  62%  of 
exposed  health  workers  received  immediate 
serology, follow up and screening as of the first day 
of exposure, 12% after 3 months and 36% after 6 
months.  No  seroconversion  case  was  noted. 
Cleaning staff and hygiene workers are at high risk 
of blood contamination as well as nurses, and more 
than  one-third  of  injuries  occurred  because  of 
mismanagement  of  healthcare  waste  produced  in 
the hospital environment, where needles were not 
disposed of appropriately in a hard container. Thus, 
41.66% of injuries could be avoided if objects were 
thrown away correctly in specific containers. It is 
urgent to raise awareness of health care personnel 
and strengthen adherence to standard precautions as 
well  as  to  provide  suitable  containers  for  the 
collection  and  disposal  of  needles  and  sharp 
objects.
87
HCV in  Morocco:  HCV  prevalence  rate  in 
Morocco  is  estimated  to  be  1.93  %.
88 However, 
higher  HCV  prevalence  rates  reaching  35.1  and 
42.4%  are detected among special populations such 
as  patients  undergoing  haemodialysis  and 
haemophiliacs respectively.
89,90,91
The prevalent HCV genotypes in Morroco are 
1b  (47.6%),  2a/2c  (37.1%)  and  1a  (2.8%)  . 
Interestingly, the HCV genotypes distribution varies 
with age as genotype 1b is more prevalent among 
older  patients,  whereas  subtype  2a/2c  is  mainly 
found among younger ones. 
88 Although Morocco 
belongs  to  the  African  continent,  the  circulating Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
HCV  strains  are  similar  to  those  observed  in 
Europe.
Hepatitis D Virus (HDV) Infection
Chronic  hepatitis  D  virus  (HDV)  infection  is 
still  an  important  health  problem  in  the 
Mediterranean basin region such as in Italy where 
coinfection  with  HDV  was  reported  in  9.7%.
92 
Hepatitis D virus (HDV)  is an RNA virus that is 
structurally unrelated to hepatitis A, B, or C virus. It 
was. HDV causes a unique infection that requires 
the  assistance  of  viral  particles  from  HBV    to 
replicate  and  infect  other  hepatocytes.  Its  clinical 
course is varied and ranges from acute self-limited 
infection to  acute  fulminant  liver failure.  Chronic 
liver infection  can  lead to  end-stage liver disease 
and associated complications. 
92
Approximately 15  million people  are infected 
worldwide. North Africa and  the Middle East are 
considered regions that high prevalence  of   HDV 
infections. HDV infection is not associated with a 
sex  predilection.  HDV infection  is more common 
among  adults  than  children.  However,  children 
from underdeveloped, HDV-endemic countries are 
more  likely  to  contract  HDV  infection  through 
breaks  in  the  skin  due  to  the  presence  of  skin 
lesions.
93
HDV in Egypt: Hepatitis D virus (HDV) infection 
among Egyptian HBV carriers and patients  has not 
been  adequately  evaluated.  Earlier  studies 
conducted in 1990, demonstrated HDV antibodies 
in 16.94% of patients with acute HBV and 23.53% 
in patients with chronic HBV. 
94,
95 A more recent 
study detected anti-HDV in 20% of HBsAg positive  
subjects and HDV RNA 60%, The proportion of the 
patients  with  liver  disease  was  higher  in  HBV 
carriers of anti-HDV positive with HDV RNA than 
in HBV carriers of anti-HDV positive without HDV 
RNA (P < 0.05). Phylogenetic analysis based on the 
sequences in nucleotide position 853-1267 of HDV 
revealed  HDV  genotype  92.1% of  the  samples 
confirming the prevalence of HBV genotype D and 
HDV genotype I are most prevalent in Egypt. 
96 In a 
prospective  study  of  45  consecutively  Egyptian 
children (2-15 years) with chronic hepatitis B, anti-
delta antibody (IgG anti-HD) was detected in only 
four  children with  an  overall  prevalence  of  8.9% 
(4/45).  A  substantial  association  between  delta 
infection  and  the  state  of  hepatic  illness  was 
detected.
97
HDV in Tunisia: Screening of serum samples from 
33,363  healthy  people  in  Tunisia  for  serological 
markers of hepatitis B and delta showed an overall 
seroprevalence  for  HDV  of    0.4%.  HDV 
superinfection  occurred  later  than  HBV  and 
increased  with  age  in  parallel  with  HBV.  HDV
superinfection  seems  common  in  Tunisia  and 
occurs in almost 44% of individuals infected with 
HBV. 
HDV in Morocco: The incidence of delta infections 
in Morocco seems to be very low in Morocco. In an 
attempt  understand  the  pathogenesis  of  severe 
hepatitis  B  and  acute  HBV  fulminanat    hepatitis 
observed in this country. Besides one patient with 
cirrhosis and positive D Ab, neither D Ag nor D Ab 
is found,. In contrast with the high endemicity of 
delta  agent  reported  in  other  countries  of  North 
Africa.
98 Considering  the  possibility  the  high 
frequence of  high rate of severe hepatitis B (HB) 
observed in this country could be the contemporary 
presence of HDV , the presence of delta antigen (D 
Ag) and antibodies to delta agent (D Ab) was tested 
by radio-immuno-assay in the sera from 85 HBs Ag 
positive  patients,  pitalized  in  Casablanca:  among 
them 57 suffered from acute or fulminant HB (12 
deceased), 10 from chronic hepatitis and 18 from 
cirrhosis.  Neither  D  Ag  nor  D  Ab  were  found, 
excepted  once  in  a  patient  with  cirrhosis  having 
shown the  presence of D Ab.
98
Hepatitis E Virus (HEV) Infection
Hepatitis  E  (HEV),  previously  known  as 
epidemic non-A, non-B hepatitis, is a positive-sense 
single-stranded RNA  icosahedral  virus with  a 7.5 
kilobase genome. HEV as the prototypic memberof 
the  genus  Hepevirus. 
99 HEV  has  been  classified 
further into  four  major  genotypes  (I  to  IV). 
Genotype  I  includes Asian  strains  from  India, 
Burma, Nepal, China, and and African strains from 
Chad, Algeria,  Tunisia,  Morocco,  Egypt,  and 
Namibia.
100
This  enterically  transmitted  virus  is  prevalent  
throughout  much  of  the  developing  world.  It  is 
constantly  present  (endemic)  in  countries  where 
human waste is allowed to get into drinking water 
without  first  being  purified.  Large  outbreaks 
(epidemics)  linked  to  contaminated  waterborne 
sources  have  occurred  in  the  Indian  subcontinent 
and South American countries where there is poor 
sanitation.    HEV  is  also  a  zoonosis.  Anti-HEV 
antibodies  have  been  detected  in  rodent,  swine, 
sheep, bovine and poultry. 
99, 100
In  general,  hepatitis  E  is  a  short-lived,  self-
limiting  viral  infection  followed  by  recovery. 
Prolonged viraemia or faecal shedding are unusual 
and chronic infection does not occur. The incidence 
of  hepatitis  E  is  highest  in  juveniles  and  adults 
between the  ages  of  15  and  40.  Though  children Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
often  contract  this  infection  as  well,  they  less 
frequently become symptomatic. Mortality rates are 
generally  low.  Occasionally,  a  fulminant  form  of 
hepatitis develops, with  overall patient population 
mortality  rates  ranging  between  0.5%  - 4.0%. 
Fulminate  hepatitis  occurs  more  frequently  in 
pregnancy  and  induces  a  mortality  rate  of  20% 
among pregnant women in the 3rd trimester and can 
also cause premature births.
99,100
The  prevalence  and  endemicity  of  HEV  vary  
across    Southern  Mediterranean  countries.  The 
features  of  HEV  infection  in  North    Africa  is 
different  from  that  in  the  Indian  subcontinent. 
Despite  the  high  prevalence  rates  in  southern 
Mediterranean  countries,  HEV  infection  is  rarely 
symptomatic in the region and fulminant hepatitis 
cases  among  pregnant  women  are  uncommon. 
However,  given  that  there  is  no  immunization 
against HEV, travelers from non-endemic areas to 
these countries must be aware of the risk of HEV 
infection  and  should  adhere  to  strict  hygienic 
measures, such as drinking bottled water and eating 
cooked food.
HEV  in  Egypt: Hepatitis  E  virus  is  probably 
endemic  in  Egypt  and  seems  to  be  a  frequent 
infection.  Genotypic  characterization  of  HEV 
circulating  in  Egypt showed the  predominance  of 
genotype  1  HEV  related  to  other  North  African 
isolates is circulating in acute symptomatic patients 
in Egypt. 
101
HEV  accounts  for  20—40%  of  adult  and 
pediatric hospitalized cases of acute viral hepatitis. 
67,95,  101  Community  surveillance  revealed  a  high 
prevalence  of  anti-HEV  antibodies  within  several 
rural populations 
102, 103, 104  A cross sectional survey 
in  several  villages  in  Upper  Egypt  and  the  Nile 
Delta  revealed  anti-HEV  antibodies  in  67.7%  of 
healthy adults
102 while screening of Egyptian  blood 
donors in Cairo demonstrated  anti-HEV antibodies 
in 24% of studied subjects.
The seroprevalence of anti-HEV is high among 
Egyptian children and the rate of positive antibodies 
increases with age. In the first decade of life, the 
prevalence of antibodies has been shown  to exceed 
60%  then it peaked to 76% in the second decade 
and  remained  around  70%  thereafter.  HEV 
serological  markers  are  frequently  encountered 
among  children  with  acute  viral  hepatitis  in 
conjunction with hepatitis B viruses. Dual infection
with HEV and other hepatotropic viruses has been 
reported  in  children  with  great  elevation    of 
aspartate  and  alanine  aminotransferases.  Among 
children (1-11 years old), with acute symptomatic 
hepatitis,  HEV was recognized as etiological factor 
in 22% of cases.
102
The prevalence of HEV antibodies in pregnant 
females  in  rural  areas  in  Egypt  is  very  high.  A 
cross-sectional  survey  of  a  cohort  of  pregnant 
women  living  in  three  rural  villages  in  the  Nile 
Delta  demonstrates  the  high  prevalence  of  anti-
HEV  that  reaches  85%.  suggesting    universal 
community exposure to this enterically transmitted 
virus. Despite reports of  fulminant HEV hepatitis 
during  pregnancy  in  Asia,  there  is  little evidence 
that  HEV-caused  overt  hepatitis  in  the  pregnant 
women and there have been no reports of the effects 
of HEV on pregnant women and their offspring in 
Egypt. 
105
Thus, the prevalence of HEV in Egypt is among 
the highest reported in the world.  Despite the very 
high prevalence of anti-HEV, HEV epidemics are 
uncommon  in  Egypt  and .almost  no  one  of  the 
screened subjects gave a prior history of jaundice, 
hepatitis  or  liver  disease,  and  none  of  these 
symptoms were significantly associated with  anti-
HEV. This lack of HEV-associated morbidity could 
be due to the presence of a less virulent circulating 
strain of HEV in the population (and possibly in all 
of Egypt); the presence of cross-reacting antibodies 
to an HEV-like virus which is not associated with 
clinical disease; or a high prevalence of exposures 
during the early years, which may be more likely to 
cause asymptomatic, anicteric illness, as is the case 
for HAV in endemic regions Exposures to HEV in 
early  childhood  may  modify  responses  to 
subsequent exposures, such that clinical illness due 
to HEV is rare, as it is in endemic HAV. 
101
HEV  in  Libya:  Epidemic  and  sporadic  water-
related  diseases  that  might  be  attributes  to  HEV 
have  been  reported  in  Libya.
19,106  However,  no 
accurate  estimates  of  the  prevalence  of  HEV  are  
available. Transmission of the HEV in Libya might 
be related to eating raw or uncooked shellfish. Farm 
animals, may serve as a viral reservoirs as HEV is 
one of the few viruses which has been shown to be 
transmitted directly from animals through food
HEV  in  Tunisia:  This  prevalence  of  HEV  in 
Tunisia is  about  4.3%. 
20 No epidemics attributed 
to HEV have been reported in Tunisia suggesting 
that  the  virus  might  be  circulating  among  the 
Tunisian population as sporadic cases. Higher anti-
HEV  IgG  prevalence rates  reaching  12.1  %  have 
been  reported  among  pregnant  women.  In 
multivariate  analysis,  age  (>30  years)  and  the 
number of persons per room (>2) in the house were 
independent  factors  predicting  HEV  infection. 
History of agricultural work, kind of water, sewage Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
treatment, use detergent to wash vegetables, contact 
with  animals  and parenteral  risk  factors were not 
correlated with the presence of anti-HEV IgG. 
107
HEV in Algeria: Hepatitis E is endemic in Algeria 
but  the  accurate  ratesare  not  available.  Sporadic 
cases frequently emerge or may go unrecognized or 
under-reported.  However,  several  epidemics  of 
hepatitis E have been reported in Algeria such as 
the HEV) Algerian epidemic between 1978-1980 
and the epidemic  in Tanefdour, Algeria,  in 1986-
1987. 
108 Before  the  identification  of  hepatitis  E 
virus  in  1990,  such  hepatitis  outbreaks  were 
denominated  enterically-transmitted  non-A,  non-B 
hepatitis.  In  January  and  February  1987,  an 
outbreak of acute hepatitis occurred in the eastern 
territories  of  Algeria.  Among  the  affected 
individuals, two pregnant women died by fulminant 
hepatitis. The epidemiological investigation traced 
the  epidemic  to  a  common  source  water 
contamination. Genotyping of the isolates showed 
that all the cases were due to HEV genotype I. Most 
isolates  shared  99.7-100  %  sequence  identity  and 
the  remainder  showed  1-1.3  %  divergence. 
Interestingly,  intra-patient  heterogeneity  revealed 
sequence  diversity  ranging  from  0.11  to  3.4 
suggesting a probable quasispecies organization of 
HEV  during  epidemics  and  could  explain  the 
adaptable behavior of the virus in the host-pathogen 
interrelations.  Comparing  the  partial  nucleotide 
sequences  and  derived  peptide  sequences  of 
hepatitis  E  virus  (HEV)  from  two  outbreaks  of 
hepatitis  E  in  Algeria  and  Chad  revealed  92  and 
95%, homology at the nucleic acid level and 98% 
the  peptide level  respectively. 
108,109    Thus,  the 
African  strains  of  HEV  appear  to  be  a  distinct 
phylogenetic group, separate from the Mexican and 
Asian strains.
HEV  in  Morocco:  HEV  is  also  endemic  in 
Morocco.  Among  healthy  adult  Moroccans,  anti-
HEV IgG  has been detected in 6.1% - 10.4% of 
subjects  particularly  in  the west  and the  south of 
Morocco. Subclinical HEV infection is frequent in 
children  and  young  adults.  A  longitudinal  study 
showed  that  anti-HEV  IgG  in  healthy  contacts 
decreased significantly after 30 years of age.  The 
incidence of clinical acute HEV infections increased 
significantly with age.
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In 1994, an  of acute HEV outbreak erupted  in 
the south of Morocco. HEV was confirmed  using 
recombinant  antigen-based  enzyme  immunoassays 
and reverse transcription polymerase chain reaction 
in  77.3% of  patients.  Furthermore, HEV-specific 
IgM  was  positive  in  84.0%  of  cases  and  was 
associated  with  subclinical  HEV  infection  in  
contacts  of  index cases.   Faecal contamination of 
drinking water samples collected from the epidemic Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
city  was  observed.  It  also  appeared  that  primary 
infection with HEV accounted for more than 86% 
of the cases. A longitudinal study showed waning of 
anti-HEV  antibodies  in  patients  and  healthy 
contacts six months after the initial testing. 
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Conclusions:  Taken  together,  the  epidemiology, 
frequency  and  patterns  of  hepatitis  viruses  show 
variations across the Southern Mediterranean region 
depending  on  several  demographic  and 
socioeconomic  factors.  The  prevalence  of  viral 
hepatitis  infection is  still  high  and  represents  a 
serious public health challenge Hepatitis B and C 
viruses remain to  be the  major causes of  chronic 
hepatitis  in  the  region.  Hepatitis  A  and  E  are 
endemic  in  the  region  and  despite  the  mainly 
subclinical  features  of  the  infections  among 
residents, HAV and HEV represent a risk to tourists 
and expatriates visiting the Southern Mediterranean 
countries.  Better  control  of  viral  hepatitis  is 
required  to  decrease  the  burden  of  the  disease. 
Immunization against hepatitis A virus and hepatitis 
B  virus  universal  use  of  disposable  syringes  and 
implementation  of  better  hygienic  conditions  are 
crucial  measures  to  reduce  the  impact  of  viral 
hepatitis in South Mediterranean countries.  
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